Companies › Zhejiang Sunshine Mandi Pharmaceutical
2 active drug programs in 5 registered trials: 2 Phase 3, 2 Phase 2, 1 Phase 1; Immunology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Minoxidil Sulfonylurea receptor 2, Kir6.2 opener | Ion channels, ABCC9 | Phase 3 | Androgenetic Alopecia | Dec 2027 |
| Clascoterone Androgen Receptor antagonist | AR | Phase 3 | Acne Vulgaris; Papular-pustular Rosacea; Pilonidal Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06952517 | Clascoterone | Phase 2 | Papular-pustular Rosacea | Immunology | Sep 2025 |
| NCT05891795 | Clascoterone | Phase 1 | Acne Vulgaris | Immunology | Jan 2026 |
| NCT06403501 | Clascoterone | Phase 3 | Acne Vulgaris | Immunology | Oct 2026 |
| NCT07080931 | Minoxidil | Phase 3 | Androgenetic Alopecia | Immunology | Dec 2027 |
| NCT06286397 | Clascoterone | Phase 2 | Pilonidal Disease | Immunology | Jan 2028 |
Industrial Farmacéutica Cantabria Biopharma Plasma Psoriasis Research Institute of Guangzhou KalVista Pharmaceuticals Triple Hair
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.